Market Data 
Markets
Replies to post #41215 on SiNtx Technologies Inc (SINT)
Catalyst Capital Group Inc. has launched a lawsuit against Anson Group Canada, a privately held asset manager with operations in Canada and Texas, and Toronto-based private equity firm West Face Capital Inc., accusing them of participating in a “manipulative ‘short and distort’ campaign.”
The alleged target was publicly traded Catalyst subsidiary Callidus Capital Corp., claims the lawsuit, which dubs the Anson, West Face and several associated and unrelated individuals as “Wolfpack Conspirators.”
The lawsuit, filed Tuesday in Ontario’s Superior Court of Justice, claims the group targeted Callidus with a short-selling strategy that involved coordinating with and providing financial support to a group of borrowers who had defaulted on loans to Callidus, and were fighting to prevent Callidus from collecting.
It also alleges use and attempted use of the news media to further their short-selling campaign, improper use of a new regulatory whistle-blowing program, and coordinated buying and selling of shares.
Among others, the lawsuit also names Anson principals Moez Kassam and Adam Spears and analyst Sunny Puri,
The minor nature of the infraction and the small size of the settlement was far from the grand hype that surrounded the investigation, which was said to involve dozens of short sellers, and numerous companies, including some blue-chip names. One fund manager called the SEC settlement with Anson “a consolation prize for some ticky tack bullshit.”
"Anson has a long history of driving differentiated and uncorrelated returns - activism is a natural extension for us," Anson's founder and chief investment officer Moez Kassam told Reuters.
The firm plans to work behind the scenes with target companies but is ready to launch public campaigns, including pushing for board seats for Gupta and others, the company said.
Mr. Adam Spears, a director of M5V, and Mr. Moez Kassam, a director of M5V
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies
AI
